The newest gene therapy treatment, Casgevy, treats sick cell disease and transfusion-dependent beta thalassemia. Its addition means that CHLA provides the most cell and gene therapy treatments for pediatrics on the West Coast, according to a Jan. 27 system news release.
CHLA’s other cell and gene therapy treatments are:
- Elevidys: treats Duchenne muscular dystrophy
- Hemgenix: treats hemophilia B
- Kymriah: treats B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma
- Luxturna: treats inherited retinal disease
- Lyfgenia: treats sickle cell disease
- Omisirge: treats patients with blood cancers undergoing umbilical cord transplantation to minimize infection risks
- Roctavian: treats hemophilia A
- Zolgensma: treats spinal muscular atrophy
- Zynteglo: treats transfusion-dependent beta thalassemia
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
